Sección de Química Terapéutica

Unidad de Química Farmacéutica

Muñoz-Torrero, Diego

Multitarget anti-Alzheimer and chemotherapeutic compounds

 

Principal Investigator: Dr. Diego Muñoz-Torrero

          Biography

 

Prof. Diego Muñoz-Torrero obtained a degree in Pharmacy at the University of Barcelona in 1989, where he performed a PhD in Pharmacy (1994, Medicinal Chemistry) under the supervision of Prof. Pelayo Camps. Thereafter, he spent 2 years at the Institut für Organische Chemie, Georg-August Universität in Göttingen, Germany, under the supervision of Prof. Reinhard Brückner.

Since 2001 he is Associate Professor of Organic and Medicinal Chemistry at the Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona (UB).

He is Vice-Dean of Research (since November 2009) and Head of the Laboratory of Pharmaceutical Chemistry (since March 2017) of the Faculty of Pharmacy and Food Sciences (UB), and belongs to the Governing Board of the Institute of Biomedicine of the UB (IBUB) since 2007.

He is a member of the Spanish Royal Society of Chemistry, Organic Chemistry Division, and the Spanish Society of Medicinal Chemistry.

He has authored 90 papers, 7 patents, and 5 book chapters, and guest-edited 5 special issues (Current Pharmaceutical Design, Current Medicinal Chemistry and Molecules) on anti-Alzheimer and multitarget drugs and 6 E-books on recent advances in pharmaceutical sciences.

He belongs to the editorial advisory board of several medicinal chemistry journals and currently serves as the Editor-in-Chief of the Medicinal Chemistry Section of the MDPI journal Molecules.

 

Link to the Google Scholar Profile

 

Molecules 2018 Travel Awards

 

Molecules 2nd Tu Youyou Award


Research lines

 

Design and synthesis of novel disease-modifying anti-Alzheimer compounds

 

Healthy ageing is becoming increasingly threatened by a number of age-related neurodegenerative diseases, including Alzheimer’s disease (AD). AD causes loss of memory and other intellectual abilities, seriously interfering with daily life quality, and finally it inexorably causes the death of the patient. Over 46 million people are currently suffering AD and, unlike other major diseases whose mortality has significantly decreased in the past decade (i.e., breast or prostate cancer, heart disease, stroke or HIV), the number of AD-related deaths increased by 68%. Likewise, the economic burden associated to AD shows a clear rising trend, currently accounting for 1.1% of the global gross domestic product. These figures will rise in the upcoming years along with the increase in life expectancy, and hence in AD prevalence that might reach 75 million people by 2030 and 131 million by 2050, thereby posing a huge pressure on society and health systems.

The elusiveness of efficacious drugs against AD greatly accounts for its fatal consequences. So far, only five drugs have been approved for the palliative treatment of AD, whereas several drug candidates directed to β-amyloid (Aβ) peptide, thought to be the main culprit of the AD, have failed to show efficacy in advanced clinical trials. This has led to the credence that Aβ is just one of the causes of AD, which might involve a complex pathological network where several key targets are jointly responsible for the neurodegeneration. Accordingly, AD could be efficiently treated only through the simultaneous modulation of several key targets.

In our research group we are synthesizing novel anti-Alzheimer drug candidates, which have been rationally designed to hit multiple key biological targets involved in the pathological network of AD such as BACE-1, Aβ and tau aggregation, MAO-B, oxidative stress, and cholinesterases.

 

 

Figure 1. Chemical structure and in vitro, ex vivo and in vivo multitarget biological profile of an anti-Alzheimer drug candidate developed in our research group (image from J. Med. Chem. 2015, 58, 6018-6032).

 

Design and synthesis of novel aminoquinoline chemotherapeutic agents

 Human African Trypanosomiasis (HAT), caused by Trypanosoma brucei gambiense or T. brucei rhodesiense, and malaria, caused by Plasmodium species, are major protozoan parasitic diseases in developing countries, where they cause over 30,000 and 1-3 million deaths annually, respectively. Despite their mortality, conventional treatments are inadequate mainly due to toxicity issues and to the emergence of resistance, especially in the case of antimalarials such as chloroquine. In this light, there is a desperate need for new and better drugs.

Huprines, developed in our group as anticholinesterase agents have been found to be potent trypanocidal agents and some of them also moderately potent against a chloroquine resistant Plasmodium falciparum strain, which makes them interesting hits with dual trypanocidal-antimalarial activity. This dual profile could result in cost-effective treatments, of special relevance in developing countries, where malaria and HAT are endemic. We have recently developed some huprine-based homo- and hetero-dimeric compounds and other quinoline-based derivatives of different structural classes that are endowed with improved anti-protozoan potencies. Further optimization of these leads will focus on improving the parasite/mammalian cell selectivity indices.

 

 

Figure 2. Structure and antitrypanosomal activity of the lead huprine and some homodimers, heterodimers, and side chain modified derivatives (image from Bioorg. Med. Chem. 2016, 24, 5162-5171).

 

Recent research projects

 

Recent research projects

 

Title of the project / contract: Hybridmoleküle und Polypharmakologie für die Wirkstoffentdeckung und -enwiklung (Hybrid molecules and polypharmacology in drug discovery and development)

Financing Firm/administration: Deutsche Forschungsgemeinschaft (DFG)

 (DFG DE 1546/8-1)

Main researcher: Michael Decker (coordinator of the project and of the University of Würzburg team); Diego Muñoz-Torrero (coordinator of the University of Barcelona team); Maria Laura Bolognesi (coordinator of the University of Bologna team)

 

Title of the project / contract: Exploración de nuevas dianas y estrategias multidiana para el diseño de compuestos contra enfermedades infecciosas y prevalentes

Financing Firm/administration: Ministerio de Economía y Competitividad (SAF2014-57094-R)

Main researcher: F. Javier Luque / Diego Muñoz-Torrero

 

Title of the project / contract: Química Farmacéutica

Financing Firm/administration: Agència de Gestió d'Ajuts Universitaris i de Recerca. Generalitat de Catalunya. AGAUR (2014SGR52)

Main researcher: Diego Muñoz-Torrero

 

Title of the project / contract: Nuevos compuestos de potencial interés industrial

Financing Firm/administration: Comisión Interministerial de Ciencia y Tecnología, CICYT (CTQ2011-22433)

Main researcher: Pelayo Camps

 

Title of the project / contract: Química Farmacéutica

Financing Firm/administration: Agència de Gestió d'Ajuts Universitaris i de Recerca. Generalitat de Catalunya. AGAUR (2009SGR1396)

Main researcher: Pelayo Camps

 

Title of the project / contract: Fons Prova de Concepte FPC-2010-19

Financing Firm/administration: Fundació Bosch i Gimpera – Barcelona Knowledge Campus (BKC)

Main researcher: Diego Muñoz-Torrero

 

Title of the project / contract: Colaboración entre la UB y Genoma España para el desarrollo de compuestos modificadores de la enfermedad de Alzheimer así como las acciones de desarrollo, de explotación industrial y de comercialización de la patente ES201000016

Financing Firm/administration: Fundación para el desarrollo de la investigación en genómica y proteómica (Genoma España)

Main researcher: Diego Muñoz-Torrero

 

 

Recent publications (last 10 years)

 

Pérez-Areales, F. J.; Betari, N.; Viayna, A.; Pont, C.; Espargaró, A.; Bartolini, M.; De Simone, A.; Rinaldi Alvarenga, J. F.; Pérez, B.; Sabate, R.; Lamuela-Raventós, R. M.; Andrisano, V.; Luque, F. J.; Muñoz-Torrero, D.

Design, synthesis, and multitarget biological profiling of second generation anti-Alzheimer rhein-huprine hybrids

Fut. Med. Chem. 2017, 9, 965-981.

 

Relat, J.; Pérez, B.; Camps, P.; Muñoz-Torrero, D.; Badia, A.; Clos, M. V.

Huprine X attenuates the neurotoxicity induced by kainic acid, especially brain inflammation

Basic Clin. Pharmacol. Toxicol. 2017, Epub ahead of print.

 

Di Pietro, O.; Juárez-Jiménez, J.; Muñoz-Torrero, D.; Laughton, C. A.; Luque, F. J.

Unveiling a novel transient druggable pocket in BACE-1 through molecular simulations: Conformational analysis and binding mode of multisite inhibitors

PLoS One 2017, 12, e0177683. Open Access Article

 

Muñoz-Torrero, D.; Mangoni, A. A.; Guillou, C.; Collina, S.; Vanden Eynde, J. J.; Rautio, J.; Keseru, G. M.; Hulme, C.; Chibale, K.; Luque, F. J.; Karaman, R.; Gütschow, M.; Liu, H.; Ragno, R.

Editorial: Breakthroughs in Medicinal Chemistry: New targets and mechanisms, new drugs, new hopes

Molecules 2017, 22, 743. Open Access Article

 

Espargaró, A.; Ginex, T.; Vadell, M. M.; Busquets, M. A.; Estelrich, J.; Muñoz-Torrero, D.; Luque, F. J.; Sabate, R.

Combined in vitro cell-based/in silico screening of naturally occurring flavonoids and phenolic compounds as potential anti-Alzheimer drugs

J. Nat. Prod. 2017, 80, 278-289.

 

Giménez-Llort, L.; Ratia, M.; Pérez, B.; Camps, P.; Muñoz-Torrero, D.; Badia, A.; Clos, M. V.

Behavioural effects of novel multitarget anticholinesterasic derivatives in Alzheimer’s disease

Behav. Pharmacol. 2017, 28, 124-131.

 

Editors: Decker, M.; Muñoz-Torrero, D.

Molecules against Alzheimer (Special issue, 16 papers)

Molecules 2016, 20-21. Open Access Issue

 

Sola, I.; Artigas, A.; Taylor, M. C.; Pérez-Areales, F. J.; Viayna, E.; Clos, M. V.; Pérez, B.; Wright, C. W.; Kelly, J. M.; Muñoz-Torrero, D.

Synthesis and biological evaluation of N-cyanoalkyl-, N-aminoalkyl-, and N-guanidinoalkyl-substituted 4-aminoquinoline derivatives as potent, selective, brain permeable antitrypanosomal agents

Bioorg. Med. Chem. 2016, 24, 5162-5171. Open Access Article

 

Di Pietro, O.; Alencar, N.; Esteban, G.; Viayna, E.; Szalaj, N.; Vázquez, J.; Juárez-Jiménez, J.; Sola, I.; Pérez, B.; Solé, M.; Unzeta, M.; Muñoz-Torrero, D.; Luque, F. J. 

Design, synthesis and biological evaluation of N-methyl-N-[(1,2,3-triazol-4-yl)alkyl]propargylamines as novel monoamine oxidase B inhibitors

Bioorg. Med. Chem. 2016, 24, 4835-4854. Open Access Article

 

Kishore, K. G.; Ghashghaei, O.; Estarellas, C.; Mestre, M. M.; Monturiol, C.; Kielland, N.; Kelly, J. M.; Fortes Francisco, A.; Jayawardhana, S.; Muñoz-Torrero, D.; Pérez, B.; Luque, F. J.; Gámez-Montaño, R.; Lavilla, R.

Insertion of isocyanides into N-Si bonds: Multicomponent reactions with azines leading to potent antiparasitic compounds

Angew. Chem. Int. Ed. 2016, 55, 8994-8998.

 

Espargaró, A.; Medina, A.; Di Pietro, O.; Muñoz-Torrero, D.; Sabate, R.

Ultra rapid in vivo screening for anti-Alzheimer anti-amyloid drugs

Sci. Rep. 2016, 6, 23349. Open Access Article

 

Serrano, F. G.; Tapia-Rojas, C.; Carvajal, F. J.; Cisternas, P.; Viayna, E.; Sola, I.; Muñoz-Torrero, D.; Inestrosa, N. C.

Rhein-huprine derivatives reduce cognitive impairment, synaptic failure and amyloid

pathology in AβPPswe/PS-1 mice of different ages

Curr. Alzheimer Res. 2016, 13, 1017-1029.

 

Navarro, S.; Carija, A.; Muñoz-Torrero, D.; Ventura, S.

A fast and specific method to screen for intracellular amyloid inhibitors using bacterial model systems

Eur. J. Med. Chem. 2016, 121, 785-792.

 

Sola, I.; Aso, E.; Frattini, D.; López-González, I.; Espargaró, A.; Sabaté, R.; Di Pietro, O.; Luque, F. J.; Clos, M. V.; Ferrer, I.; Muñoz-Torrero, D.

Novel levetiracetam derivatives that are effective against the Alzheimer-like phenotype in mice: synthesis, in vitro, ex vivo and in vivo efficacy studies

J. Med. Chem. 2015, 58, 6018-6032.

 

Di Pietro, O.; Vicente-García, E.; Taylor, M. C.; Berenguer, D.; Viayna, E.; Lanzoni, A.; Sola, I.; Sayago, H.; Riera, C.; Fisa, R.; Clos, M. V.; Pérez, B.; Kelly, J. M.; Lavilla, R.; Muñoz-Torrero, D.

Multicomponent-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity

Eur. J. Med. Chem. 2015, 105, 120-137. Open Access Article

 

Sola, I.; Castellà, S.; Viayna, E.; Galdeano, C.; Taylor, M. C.; Gbedema, S. Y.; Pérez, B.; Clos, M. V.; Jones, D. C.; Fairlamb, A. H.; Wright, C. W.; Kelly, J. M.; Muñoz-Torrero, D.

Synthesis, biological profiling and mechanistic studies of 4-aminoquinoline-based heterodimeric compounds with dual trypanocidal-antiplasmodial activity

Bioorg. Med. Chem. 2015, 23, 5156-5167 (Special issue New Developments in Antiinfectives Research).

 

Sola, I.; Viayna, E.; Gómez, T.; Galdeano, C.; Cassina, M.; Camps, P.; Romeo, M.; Diomede, L.; Salmona, M.; Franco, P.; Schaeffer, M.; Colantuono, D.; Robin, D.; Brunner, D.; Taub, N.; Hutter-Paier, B.; Muñoz-Torrero, D.

Multigram synthesis and in vivo efficacy studies of a novel multitarget anti-Alzheimer's compound

Molecules 2015, 20, 4492-4515. Open Access Article

 

Torrent, J.; Vilchez-Acosta, A.; Muñoz-Torrero, D.; Trovaslet, M.; Nachon, F.; Chatonnet, A.; Grznarova, K.; Acquatella-Tran Van Ba, I.; Le Goffic, R.; Herzog, L.; Béringue, V.; Rezaei, H.;

Interaction of prion protein with acetylcholinesterase: potential pathobiological implications in prion diseases

Acta Neuropathol. Commun. 2015, 3:18 Open Access Article

 

Giménez-Llort, L.; Ratia, M.; Pérez, B.; Camps, P.; Muñoz-Torrero, D.; Badia, A.; Clos, M.V.

AVCRI104P3, a novel multitarget compound with cognition-enhancing and anxyolitic actitivies: Studies in cognitively poor middle-aged mice

Behav. Brain Res. 2015, 286, 97-103.

 

Viayna, E.; Sola, I.; Bartolini, M.; De Simone, A.; Tapia-Rojas, C.; Serrano, F. G.; Sabaté, R.; Juárez-Jiménez, J.; Pérez, B.; Luque, F. J.; Andrisano, V.; Clos, M. V.; Inestrosa, N. C.; Muñoz-Torrero, D.

Synthesis and multi-target biological profiling of a novel family of rhein derivatives as disease-modifying anti-Alzheimer agents

J. Med. Chem. 2014, 57, 2549-2567.

 

Sola, I.; Artigas, A.; Taylor, M. C.; Gbedema, S. Y.; Pérez, B.; Clos, M. V.; Wright, C. W.; Kelly, J. M.; Muñoz-Torrero, D.

Synthesis and antiprotozoal activity of oligomethylene- and p-phenylene-bis(methylene)-linked bis(+)-huprines

Bioorg. Med. Chem. Lett. 2014, 24, 5435-5438.

 

Pérez-Areales, F. J.; Di Pietro. O.; Espargaró, A.; Vallverdú-Queralt, A.; Galdeano, C.; Ragusa, I. M.; Viayna, E.; Guillou, C.; Clos, M. V.; Pérez, B.; Sabaté, R.; Lamuela-Raventós, R. M.; Luque, F. J.; Muñoz-Torrero, D.

Shogaol-huprine hybrids: Dual antioxidant and anticholinesterase agents with beta-amyloid and tau anti-aggregating properties

Bioorg. Med. Chem. 2014, 22, 5298-5307.

 

Di Pietro, O.; Pérez-Areales, F.J.; Juárez-Jiménez, J.; Espargaró, A.; Clos, M.V.; Pérez, B.; Lavilla, R.; Sabaté, R.; Luque, F.J.; Muñoz-Torrero, D.

Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting beta-amyloid, tau, and cholinesterase pathologies

Eur. J. Med. Chem. 2014, 84, 107-117.

 

Di Pietro, O.; Viayna, E.; Vicente-García, E.; Bartolini, M.; Ramón, R.; Juárez-Jiménez, J.; Clos, M.V.; Pérez, B.; Andrisano, V.; Luque, F.J.; Lavilla, R.; Muñoz-Torrero, D.

1,2,3,4-Tetrahydrobenzo[h][1,6]naphthyridines as a new family of potent peripheral-to-midgorge-site inhibitors of acetylcholinesterase: synthesis, pharmacological evaluation and mechanistic studies

Eur. J. Med. Chem. 2014, 73, 141-152.

 

Pouplana, S.; Espargaró, A.; Galdeano, C.; Viayna, E.; Sola, I.; Ventura, S.; Muñoz-Torrero, D.; Sabate, R.

Thioflavin-S staining of bacterial inclusion bodies for the fast, simple, and inexpensive screening of amyloid aggregation inhibitors

Curr. Med. Chem. 2014, 21, 1152-1159.

 

Muñoz-Torrero, D.; Ferrer, I.; Sola, I.; Aso, E.

Multi-target drug compounds for the treatment of neurodegenerative disorders

Patent WO2014206877 A1 Date of priority: 2014

Main institution: Universitat de Barcelona / Institut d'Investigació Biomèdica de Bellvitge IDIBELL

 

Pera, M.; Camps, P.; Muñoz-Torrero, D.; Perez, B.; Badia, A.; Clos Guillen, M.V

Undifferentiated and differentiated PC12 cells protected by huprines against injury induced by hydrogen peroxide

PLoS One 2013, 8, e74344. Open Access Article

 

Viayna, E.; Sabate, R.; Muñoz-Torrero, D.

Dual inhibitors of beta-amyloid aggregation and acetylcholinesterase as multi-target anti-Alzheimer drug candidates

Curr. Top. Med. Chem. 2013, 13, 1820-1842.

 

Editor: Muñoz-Torrero, D.

Complexity against complexity: Multitarget drugs (Hot Topic issue, 12 chapters)

Curr. Med. Chem. 2013, 20, 1621-1799.

 

Viayna, E.; Sola, I.; Di Pietro, O.; Muñoz-Torrero, D.

Human disease and drug pharmacology, complex as real life

Curr. Med. Chem. 2013, 20, 1623-1634.

 

Ratia, M.; Giménez-Llort, L.; Camps, P.; Muñoz-Torrero, D.; Pérez, B.; Clos, M.V.; Badia, A.

Huprine X and huperzine A improve cognition and regulate some neurochemical processes related with Alzheimer's disease in triple transgenic mice (3xTg-AD)

Neurodegener. Dis. 2013, 11, 129-140.

 

Muñoz-Torrero, D.; Inestrosa, N.C.; Viayna, E.; Sola, I.; Vázquez, S.

Beta-amyloid-directed multitarget compounds for the treatment of Alzheimer’s disease

Patent PCT/EP2013/059683; US 9,238,626 B2. Date of priority: 2013

Main institution: Universitat de Barcelona / Pontificia Universidad Católica de Chile

 

Galdeano, C.; Viayna, E.; Sola, I.; Formosa, X.; Camps, P.; Badia, A.; Clos, M. V.; Relat, J.; Ratia, M.; Bartolini, M.; Mancini, F.; Andrisano, V.; Salmona, M.; Minguillón, C.; González-Muñoz, G. C.; Rodríguez-Franco, M. I.; Bidon-Chanal, A.; Luque, F. J.; Muñoz-Torrero, D.

Huprine-tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer’s and prion diseases

J. Med. Chem. 2012, 55, 661-669.

 

Muñoz-Torrero, D.; Pera, M.; Relat, J.; Ratia, M.; Galdeano, C.; Viayna, E.; Sola, I.; Formosa, X.; Camps, P.; Badia, A.; Clos, M. V.

Expanding the multipotent profile of huprine-tacrine heterodimers as disease-modifying anti-Alzheimer agents

Neurodegener. Dis. 2012, 10, 96-99.

 

Defaux, J.; Sala, M.; Formosa, X.; Galdeano, C.; Taylor, M. C.; Alobaid, W. A. A.; Kelly, J. M.; Wright, C. W.; Camps, P.; Muñoz-Torrero, D.

Huprines as a new family of dual acting trypanocidal-antiplasmodial agents

Bioorg. Med. Chem. 2011, 19, 1702-1707. Open Access Article

 

Viayna, E.; Gómez, T.; Galdeano, C.; Ramírez, L.; Ratia, M.; Badia, A.; Clos, M. V.; Verdaguer, E.; Junyent, F.; Camins, A.; Pallàs, M.; Bartolini, M.; Mancini, F.; Andrisano, V.; Arce, M. P.; Rodríguez-Franco, M. I.; Bidon-Chanal, A.; Luque, F. J.; Camps, P.; Muñoz-Torrero, D.

Novel huprine derivatives with inhibitory activity toward beta-amyloid aggregation and formation as disease-modifying anti-Alzheimer drug candidates

ChemMedChem 2010, 5, 1855-1870.

 

Muñoz-Torrero, D.; Camps, P.; Gómez, T.; Viayna, E.; Galdeano, C.

Compuestos multifuncionales modificadores de la enfermedad de Alzheimer para el tratamiento de esta enfermedad

Patent P201000016 (PCT/ES2010/070862) Date of priority: 2010

Main institution: Universitat de Barcelona

 

Galdeano, C.; Viayna, E.; Arroyo, P.; Bidon-Chanal, A.; Blas, J. R.; Muñoz-Torrero, D.; Luque, F. J.

Structural determinants of the multifunctional profile of dual binding site acetylcholinesterase inhibitors as anti-Alzheimer agents

Curr. Pharm. Des. 2010, 16, 2818-2836.

 

Ratia, M.; Giménez-Llort, L.; Camps, P.; Muñoz-Torrero, D.; Clos, M. V.; Badia, A.

Behavioural effects and regulation of PKC alpha and MAPK by huprine X in middle aged mice

Pharmacol. Biochem. Behav. 2010, 95, 485-493.

 

Hedberg, M. M.; Clos, M. V.; Ratia, M.; Gonzalez, D.; Unger Lithner, C.; Camps, P.; Muñoz-Torrero, D.; Badia, A.; Giménez-Llort, L.; Nordberg, A.

Effect of huprine X on Abeta, synaptophysin and alpha7 neuronal nicotinic acetylcholine receptors in the brain of 3xTg-AD and APPswe transgenic mice

Neurodegener. Dis. 2010, 7, 379-388.

 

Camps, P.; Formosa, X. ; Galdeano, C.; Gómez, T.; Muñoz-Torrero, D.; Ramírez, L.; Viayna, E.; Gómez, E.; Isambert, N.; Lavilla, R.; Badia, A.; Clos, M. V.; Bartolini, M.; Mancini, F.; Andrisano, V.; Bidon-Chanal, A.; Huertas, O.; Dafni, T.; Luque, F. J.

Tacrine-based dual binding site acetylcholinesterase inhibitors as potential disease-modifying anti-Alzheimer drug candidates

Chem.-Biol. Interact. 2010, 187, 411-415.

 

Camps, P.; Formosa, X. ; Galdeano, C.; Muñoz-Torrero, D.; Ramírez, L.; Gómez, E.; Isambert, N.; Lavilla, R.; Badia, A.; Clos, M. V.; Bartolini, M.; Mancini, F.; Andrisano, V.; Arce, M. P.; Rodríguez-Franco, M. I.; Huertas, O.; Dafni, T.; Luque, F. J.

Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and ²-amyloid-directed anti-Alzheimer compounds

J. Med. Chem. 2009, 52, 5365-5379.

 

Oluwafemi, A.J.; Okanla, E.O.; Camps, P.; Muñoz-Torrero, D.; Mackey, Z.B.; Chiang, P.K.; Seville, S.; Wright, C.W.

Evaluation of cryptolepine and huperzine derivatives as lead compounds towards new agents for the treatment of human African trypanosomiasis

Nat. Prod. Commun. 2009, 4, 193-198.

 

Muñoz-Torrero, D.

Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease

Curr. Med. Chem. 2008, 15, 2433-2455.

 

Camps, P.; Formosa, X. ; Galdeano, C.; Gómez, T.; Muñoz-Torrero, D.; Scarpellini, M.; Viayna, E.; Badia, A.; Clos, M.V.; Camins, A.; Pallàs, M.; Bartolini, M.; Mancini, F.; Andrisano, V.; Estelrich, J.; Lizondo, M.; Bidon-Chanal, A.; Luque, F. J.

Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation

J. Med. Chem. 2008, 51, 3588-3598.

 

Muñoz-Torrero, D.; Camps, P.

Huprines for Alzheimer's disease drug development

Expert Opin. Drug Discovery 2008, 3, 65-81.

 

 

Current collaborations

 

Dr. F. Javier Luque, Departament de Nutrició, Ciències de l’Alimentació i Gastronomia, Facultat de Farmàcia i Ciències de l’Alimentació, Universitat de Barcelona (Spain)

 

Dr. Raimon Sabaté, Departament de Farmàcia i Tecnologia Farmacèutica i Fisicoquímica, Facultat de Farmàcia i Ciències de l’Alimentació, Universitat de Barcelona (Spain)

 

Dr. M. Victòria Clos / Dr. Belén Pérez, Departament de Farmacologia, de Terapèutica i de Toxicologia, Universitat Autònoma de Barcelona (Spain)

 

Dr. Manuela Bartolini, Department of Pharmacy and Biotechnology, University of Bologna (Italy)

 

Dr. Vincenza Andrisano / Dr. Angela De Simone, Department for Life Quality Studies, University of Bologna (Italy)

 

Dr. Nibaldo C. Inestrosa, Centro de Envejecimiento y Regeneración (CARE), Departamento de Biología Celular y Molecular, Pontificia Universidad Católica de Chile (Chile)

 

Dr. Isidro Ferrer / Dr. Ester Aso, Institut de Neuropatologia, Servei d’Anatomia Patolo?gica, IDIBELL-Hospital Universitari de Bellvitge (Spain)

 

Dr. Rodolfo Lavilla, Departament de Farmacologia, Toxicologia i Química Terapèutica, Facultat de Farmàcia i Ciències de l’Alimentació, Universitat de Barcelona (Spain)

 

Dr. John M. Kelly, London School of Hygiene and Tropical Medicine (United Kingdom)

 

Dr. Colin W. Wrigth, Bradford School of Pharmacy (United Kingdom)

 

Dr. Mercedes Unzeta, Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona (Spain)

 

Dr. Salvador Ventura, Institut de Biotecnologia i Biomedicina and Departament de Bioquimica i Biologia Molecular, Universitat Autònoma de Barcelona (Spain)

 

Dr. José Manuel Bautista, Departamento de Bioquímica y Biología Molecular IV and Instituto de Investigación Hospital 12 de Octubre, Universidad Complutense de Madrid (Spain)

 

Dr. Francesc Xavier Sureda, Departament de Ciències Mèdiques Bàsiques, Universitat Rovira i Virgili (Spain)

 

Dr. Mario Salmona / Dr. Luisa Diomede, Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche “Mario Negri”, Milan (Italy)

 

Dr. Pierre-Yves Renard / Dr. Ludovic Jean, COBRA – CNRS UMR 6014 & FR 3038, and Université de Rouen (France)

 

Dr. Jacques-Philippe Colletier, Institut de Biologie Structurale, Grenoble (France)

 

Dr. Joan Torrent, Institut National de la Recherche Agronomique, UR892, Virologie

Immunologie Moléculaires (France)

 

Dr. Luciano Saso, Institute of Pharmacology, La Sapienza University of Rome (Italy)

 

Dr. Omidreza Firuzi, Medicinal and Natural Products Chemistry Research Center (Iran)

 

Dr. M. Cristina Riera / Dr. Roser Fisa, Departament de Biologia, Sanitat i Medi Ambient, Facultat de Farmàcia i Ciències de l’Alimentació, Universitat de Barcelona (Spain)

 

Dr. Rosa M. Lamuela-Raventós, Departament de Nutrició, Ciències de l’Alimentació i Gastronomia, Facultat de Farmàcia i Ciències de l’Alimentació, Universitat de Barcelona (Spain)

 

 

Current group members

 

Dr. Diego Muñoz-Torrero                  Associate Professor         dmunoztorrero@ub.edu

F. Javier Pérez-Areales                    PhD student                   perezareales@hotmail.com

Katia Pont                                     PhD student                   aitak1989@gmail.com